- Home
- CRNX vs MIST Comparison
CRNX vs MIST Comparison
Compare CRNX & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRNX | MIST |
|---|---|---|
| Founded | 2008 | 2003 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 176.3M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | CRNX | MIST |
|---|---|---|
| Price | $46.74 | $2.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 4 |
| Target Price | ★ $71.00 | $8.50 |
| AVG Volume (30 Days) | 983.9K | ★ 10.0M |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,535,000.00 | N/A |
| Revenue This Year | $425.41 | N/A |
| Revenue Next Year | $943.30 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 47.74 | N/A |
| 52 Week Low | $24.10 | $0.63 |
| 52 Week High | $53.55 | $3.06 |
Technical Indicators
Market Signals| Indicator | CRNX | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 49.48 | 42.10 |
| Support Level | $43.04 | $1.94 |
| Resistance Level | $48.25 | $2.14 |
| Average True Range (ATR) | 1.82 | 0.31 |
| MACD | -0.35 | -0.05 |
| Stochastic Oscillator | 46.60 | 28.97 |
Price Performance
Historical ComparisonAbout CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).